Financials

Financials in One Page

Convatec is a $2.4B chronic-care medical-products company that has transitioned from a slow-grow, post-LBO recovery story (2016-2021) into an organic-growth-and-margin-expansion story. FY2025 revenue grew 6.5% reported (6.4% organic ex-InnovaMatrix), gross margin held at 56%, and adjusted operating margin lifted ~110bps to 22.3% — the fourth consecutive year of margin progress on the road to a 24-26% target by 2027. Reported earnings are noisy: a $72M Triad/InnovaMatrix intangible impairment, plus heavy amortization of pre-IPO purchase intangibles, push reported operating margin down to 13.0% versus the adjusted 22.3%. Cash conversion is genuine — operating cash flow of $470M and free cash flow of $335M comfortably exceed reported net income of $175M, funding $300M of buybacks plus $140M of dividends in 2025. Net debt of $1,330M (2.0x adjusted EBITDA) is investment-grade across all three agencies and refinanced through 2035 with a new $500M ten-year senior unsecured note. Valuation looks reasonable on adjusted earnings (mid-teens P/E) but optical on reported earnings (mid-30s); the swing factor is whether the adjusted-vs-reported gap narrows as legacy intangible amortization rolls off. The single financial metric that matters most: adjusted operating margin progression toward 24-26% by 2027.

Revenue, Margins, and Earnings Power

Convatec sells chronic-care consumables across four franchises: Advanced Wound Care (AWC), Ostomy Care (OC), Continence Care (CC), and Infusion Care (IC). Revenue is largely recurring — patients on ostomy bags, catheters, infusion sets and wound dressings buy month after month. The business spent 2013-2020 nearly flat (revenue roughly $1.7-1.9B) as new ownership reset capital structure and product portfolio. Since 2021 the revenue line has compounded at ~5% with margin expansion on top.

The 2019 dip in operating income reflects a $192M intangible impairment under prior management. The 2025 dip reflects the $72M Triad impairment. Both prove the same point: the reported operating line is repeatedly polluted by purchase-intangible accounting from a long deal history.

Margins — The Real Story

Gross margin has stepped up from ~52% to ~56% — a 400bp gain over five years driven by manufacturing simplification, plant automation, premium product mix (ConvaFoam, Esteem Body, GentleCath Air), and pricing. That is the cleanest signal in the financials. Reported operating margin tells a noisier story; adjusted operating margin tells the real one.

460bps of adjusted margin expansion since 2021, despite the 2022-23 inflation shock. Management guides to ≥23.0% in FY26 and 24-26% by 2027. Each 100bps of margin on $2.4B of revenue is ~$24M of profit before tax — meaningful at this share count.

Half-Year Trajectory

UK reporting cadence is H1/H2 (quarterly file repeats values across the half). Convatec is not a smooth seasonal business; growth is broad-based but H2 typically larger.

The trajectory is clean: every half-year since H1 23 has been higher than the one before, an unusual achievement in medical devices given destocking, FX, and reimbursement noise. By segment, Infusion Care led FY25 organic growth at +12.5% (Neria Guard for AbbVie's Parkinson's therapy), CC at +6.6%, OC at +4.5%, AWC at +4.1% ex-InnovaMatrix. InnovaMatrix (the Triad acquisition) revenue fell 30% to $69M after a CMS reimbursement cut and is guided to ~$20M in FY26 — the small cancer in the franchise the market needs to size.

Cash Flow and Earnings Quality

Free cash flow = cash generated by operations after the capital spending needed to maintain and grow the business. For Convatec, the gap between reported net income and cash flow has been wide and consistent — earnings are real, just understated.

Operating cash flow has exceeded reported net income in every year since 2017 — usually by 2-4x. The wedge is mostly purchase-intangible amortization (~$160-200M/yr non-cash) from pre-IPO and tuck-in deals. FCF margin has held in a 9-15% band, expanded to 13.7% in 2025.

The 2022 trough is the warning: capex spiked to $144M and acquisitions consumed $173M as Convatec rebuilt manufacturing capacity (the Lia/Ostosa/Triad period). FCF has rebuilt cleanly since.

Cash-Flow Distortions to Watch

Balance Sheet and Financial Resilience

Net debt fell 42% from $1.5B in 2017 to a $0.9B trough in 2020-21, then rose with M&A and growth capex, settling at $1.33B at YE25. The 2025 rise is intentional: the company tapped a new $500M ten-year senior unsecured note to push out maturities and fund the $300M buyback. Management's target leverage of 2.0x adjusted EBITDA matches the 2025 actual — they're operating exactly at target, leaving optional capacity for opportunistic M&A or further returns.

Investment grade across all three agencies as of 2025 — a meaningful upgrade from the post-LBO B/BB era and the reason the company can raise long-dated unsecured paper. Cash itself is thin ($68M) but liquidity is supported by undrawn revolvers and ~$470M annual operating cash flow.

Goodwill and Intangibles

Acquisition-related intangibles have been amortizing down ($1.49B → $0.65B) — that is mechanically why reported margins are catching up to adjusted. Goodwill keeps creeping higher with tuck-ins. Goodwill is now 36% of total assets and 89% of equity — a real impairment risk if any single CGU underperforms (the Triad impairment is the proof of concept).

Returns, Reinvestment, and Capital Allocation

ROE / ROA measure profit per dollar of shareholder equity / total assets respectively. Reported ROE has rebuilt from sub-1% in 2019 to ~11% — respectable but not best-in-class. On adjusted earnings ($0.176 × 2.04B shares ≈ $359M), ROE would be ~22%, which is in line with quality med-tech peers (Coloplast, S&N).

Capital Allocation in 2025

This is a notable shift in the capital-allocation playbook: buybacks ($326M) outweighed M&A ($24M) for the first time in the FTSE-100 era. With investment-grade rating now secured and tuck-in M&A appetite reduced, the company is signaling that its own equity is the highest-return reinvestment opportunity — a credible call given mid-teens P/E on adjusted earnings.

Share Count and Per-Share Dynamics

Share count drifted up ~5% from 2017-2024 (SBC dilution) before the 2025 buyback retired ~90M shares (-4.4%). Adjusted EPS grew +16.0% in FY25 (17.6¢ vs 15.2¢) — the buyback contributed ~3-4 percentage points; the rest was operating leverage and lower finance costs.

Segment and Unit Economics

The segment.json probe was unavailable, but FY25 organic growth disclosure gives the franchise mix and trajectory. Convatec splits revenue across four roughly equal-weight chronic-care franchises:

Infusion Care is the standout — diabetes pump-set demand plus the Neria Guard contract for AbbVie's Parkinson's therapy. Continence Care is accelerating on GentleCath Air launches. Ostomy Care is steady and gaining a first US Group Purchasing Organisation contract in 5+ years. Advanced Wound Care ex-InnovaMatrix is healthy at +4.1%, but the Triad/InnovaMatrix revenue collapse (-30% in FY25, guided to ~$20M in FY26 from $69M in FY25) is the visible drag.

The strategically important fact: markets where Convatec has #1 or #2 share contribute over 60% of group revenue, supporting the gross margin trajectory and durable mid-single-digit organic growth.

Valuation and Market Expectations

CTEC trades at 226p (May 2026) on roughly 1.95B shares = market cap ~£4.4B (~$5.7B at GBP/USD ~1.30). Net debt $1.33B → enterprise value ~$7.0B.

Multiple Choice — Why Adjusted P/E and EV/EBITDA

For a company with substantial purchase-accounting amortization, P/E on reported EPS is misleadingly high. The right anchor is adjusted P/E (mid-teens) for a business growing high-single-digits with margin expansion to 24-26%. EV/EBITDA on adjusted EBITDA at ~9x is the cleanest cross-checks against med-device peers — between Embecta/ICUI on the cheap end and Coloplast/Insulet on the premium end.

The chart is approximate (year-end price vs adjusted EPS). The 2020-21 peak (~25-30x) reflected COVID-era medtech enthusiasm; the 2022-23 reset (~14-16x) reflected inflation and slow growth fears; 2024-25 is a 16-17x range — slightly below the company's own 5-year median and well below quality medtech peers like Coloplast (mid-20s) and Insulet (high-40s).

Bear / Base / Bull

The thesis hinges on whether the 2027 mid-20s margin target prints. If yes, the stock re-rates toward S&N/Coloplast multiples on the back of compounding adjusted EPS. If reported earnings continue to lag adjusted (impairments, restructuring), the multiple stays stuck at mid-teens.

Peer Financial Comparison

Peer columns reflect FY25 reported revenue and net income from each issuer's annual filings; Convatec margin/EPS use management's adjusted metrics; peer adj margin/FCF estimates are approximate from filings & vendor pages. Coloplast is reported in DKK and converted approximately. Use this table as a relative-positioning chart, not a transaction-grade comp.

The peer gap that matters. Convatec sits between two clusters:

• Premium chronic-care peers (Coloplast, Insulet) trade at 25-50x adjusted P/E with adj op margins of 18-27% and ROE 18-32%. Convatec is the cheap option here — close enough on margin and growth that closing the gap to Coloplast on multiples is a credible re-rate path.
• Cheap diversified medtech (Embecta, Solventum) trade at 5-7x P/E with similar revenue scale but no growth or capital-allocation story. Convatec is clearly above this cluster on quality.

S&N is the closest comp on geography and AWC overlap; its EV/EBITDA of ~12x and ROE of ~18% set a reasonable upper bound for where CTEC could re-rate without margin/growth surprises.

What to Watch in the Financials

Closing Read

The financials confirm that Convatec is in the middle of a credible margin-expansion programme: gross margin up 400bps in five years, adjusted operating margin up 460bps since 2021, FCF rebuilt to $335M, leverage at the 2.0x target with investment-grade ratings. The contradictions are concentrated in two places: the gap between reported and adjusted operating margin (driven by purchase-intangible amortization and the Triad impairment) which keeps reported P/E optically expensive, and a goodwill stack that is now 89% of equity — the Triad write-down is a small reminder that other CGUs could surprise.

The first financial metric to watch is adjusted operating margin in FY26 H1 results. Management has guided to ≥23.0% for the full year. A print of 23.0%+ keeps the 24-26% by 2027 target intact and underwrites another year of double-digit adjusted EPS growth. A print below 22.5% (margin moderation, Triad/AWC drag, or tariff cost overrun) would force the market to rebuild the entire margin runway and would likely de-rate the stock toward the bear case.